Erratum: Neoadjuvant and adjuvant pembrolizumab in resectable locally advanced, human papillomavirus⇓unrelated head and neck cancer: A multicenter, phase II trial (CLINICAL CANCER RESEARCH2020;26:5140–52 DOI: 10.1158/1078-0432.CCR-20-1695)

Ravindra Uppaluri, Katie M. Campbell, Ann Marie Egloff, Paul Zolkind, Zachary L. Skidmore, Brian Nussenbaum, Randal C. Paniello, Jason T. Rich, Ryan Jackson, Patrik Pipkorn, Loren S. Michel, Jessica Ley, Peter Oppelt, Gavin P. Dunn, Erica K. Barnell, Nicholas C. Spies, Tianxiang Lin, Tiantian Li, David T. Mulder, Youstina HannaIulia Cirlan, Trevor J. Pugh, Tenny Mudianto, Rachel Riley, Liye Zhou, Vickie Y. Jo, Matthew D. Stachler, Glenn J. Hanna, Jason Kass, Robert Haddad, Jonathan D. Schoenfeld, Evisa Gjini, Ana Lako, Wade Thorstad, Hiram A. Gay, Mackenzie Daly, Scott J. Rodig, Ian S. Hagemann, Dorina Kallogjeri, Jay F. Piccirillo, Rebecca D. Chernock, Malachi Griffith, Obi L. Griffith, Douglas R. Adkins

Research output: Contribution to journalComment/debate

1 Scopus citations

Abstract

In the original version of this article (1), Fig. 4A and B were duplicated. Figure 4B has been corrected in the latest online HTML and PDF versions of the article. The authors regret this error.

Original languageEnglish
Pages (from-to)357
Number of pages1
JournalClinical Cancer Research
Volume27
Issue number1
DOIs
StatePublished - Jan 1 2021

Fingerprint

Dive into the research topics of 'Erratum: Neoadjuvant and adjuvant pembrolizumab in resectable locally advanced, human papillomavirus⇓unrelated head and neck cancer: A multicenter, phase II trial (CLINICAL CANCER RESEARCH2020;26:5140–52 DOI: 10.1158/1078-0432.CCR-20-1695)'. Together they form a unique fingerprint.

Cite this